AVBP

AI Memo

ArriVent BioPharma

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

ARR-217 Phase 1 data interpretation • 2026-10-26

Base target: $21 / p=50% prob

Biggest risk

The pivotal FURVENT primary-endpoint miss materially weakens the lead program's first-line exon 20 insertion case. ARR-217 and ARR-002 are early-stage, and ALPACCA still carries pivotal-trial risk. [#PR-2026-10-06] Company release

Invalidation

Break below $12 or thesis failure.

What would change my mind?

ARR-217 data could establish a credible second value driver, while the separate ALPACCA PACC-mutant program and early ARR-002 trial preserve portfolio optionality. The October 19 PACC Phase 1b findings support further testing, not approval-level efficacy. [#8-K-2026-10-19] Company release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-25

Base target

$21

p=50%

Bull target

$32

p=25%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ALPACCA enrollment and PACC-mutant NSCLC evidence
ARR-002 early clinical progress
ARR-217 data could establish a credible second value driver, while the separate ALPACCA PACC-mutant program and early ARR-002 trial preserve portfolio optionality.

BearKey bullets

ALPACCA Phase 3 enrollment and eventual efficacy remain uncertain despite encouraging, nonrandomized PACC Phase 1b findings.
[#8-K-2026-10-19]
ARR-002 has only recently entered U.S.

WatchKey bullets

ARR-217 Phase 1 data interpretation

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $21 (p=50%)

Target spread vs base: +52% / -43%

Scenario probabilities

Bull Target: $32 (p=25%)Base Target: $21 (p=50%)Bear Target: $12 (p=25%)

Commentary

Recent headlines report a sharp October 6 selloff following the FURVENT miss, but a verified event-day close-to-close return is unavailable. The supplied anchor is $21.00 on October 23. The October 23 ARR-217 presentation announcement creates a near-term attention point, but neither its clinical results nor a post-announcement price reaction were verified here. News tone is negative overall; the numeric news score is a qualitative estimate. Zeros for social sentiment, options skew, short interest, and employee score mean unavailable, not neutral readings. No reliable post-FURVENT analyst target or estimate revisions were supplied. [#PR-2026-10-06] Company release [#PR-2026-10-23] Company announcement

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ALPACCA enrollment and PACC-mutant NSCLC evidence
ARR-002 early clinical progress

Scenarios

Bull Target (Scenario probability)

$32 / p=25% prob

Base Target (Scenario probability)

$21 / p=50% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-26
ARR-217 Phase 1 data interpretation
ArriVent scheduled initial ARR-217 safety and efficacy data for an October 25 ESMO presentation and an October 26 company webinar. The October 23 announcement does not disclose results, so response durability, sample size, and toxicity remain unverified here. [#PR-2026-10-23] Company announcement
Prob 95.00% • Move 8.00% • Priced-in 35.00%
EVENT2026-12-31
Firmonertinib development decision after FURVENT miss
FURVENT missed its primary blinded-review PFS endpoint: median PFS was 11.0 months at 240 mg versus 9.5 months for control (p=0.0654). ArriVent is evaluating the full dataset before choosing a development path; no decision date has been announced. The expected date is a monitoring estimate, not company guidance. [#PR-2026-10-06] Company release
Prob 65.00% • Move -10.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ALPACCA enrollment and PACC-mutant NSCLC evidence
2027-12-31
ArriVent said ALPACCA Phase 3 enrollment continues. Its October 19 release reported Phase 1b PACC-mutant NSCLC findings, including a 68% confirmed response rate at 240 mg, but those nonrandomized findings do not establish Phase 3 success and concern a different mutation population from FURVENT. The date is an analytical monitoring estimate; no ALPACCA readout date was confirmed. [#8-K-2026-10-19] Company release
Prob 60% • Move 12% • Priced-in 20%
ARR-002 early clinical progress
2027-12-31
ArriVent announced first U.S. patient dosing in the ARR-002 Phase 1 trial on October 12. Safety, tolerability, dosing, and efficacy remain to be established. The date is a monitoring estimate, not a company-promised readout. [#PR-2026-10-12] Company release
Prob 55% • Move 6% • Priced-in 15%

Risks

ALPACCA Phase 3 enrollment and eventual efficacy remain uncertain despite encouraging, nonrandomized PACC Phase 1b findings. [#8-K-2026-10-19]
ARR-002 has only recently entered U.S. Phase 1 testing; tolerability and clinical activity are unproven. [#PR-2026-10-12]
ARR-217 Phase 1 efficacy and safety details were not verified in the October 23 announcement; early data may be small or immature. [#PR-2026-10-23]
Clinical spending, reprioritization, or financing could change the June 30 company-stated runway into 2028. [#SEC-8K-2026-08-12]
FURVENT failed its primary blinded-review PFS endpoint; secondary signals do not reverse that result. [#PR-2026-10-06]

Peers

Symbol	Summary
JANX	Clinical-oncology biotech candidate in the packet's similar-market-cap group. It is a loose development-risk comparator, not a confirmed same-indication or same-modality peer.
ORIC	Targeted-oncology development comparator carried from the prior primary-source review; program, trial-stage, and cash-runway differences prevent a direct valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

JANX

Clinical-oncology biotech candidate in the packet's similar-market-cap group. It is a loose development-risk comparator, not a confirmed same-indication or same-modality peer.

ORIC

Targeted-oncology development comparator carried from the prior primary-source review; program, trial-stage, and cash-runway differences prevent a direct valuation multiple.